QD Syringe Systems®

The Next Generation of Low Dead Space Disposable Syringes

FDA ::: Warns of IV Compatibility Issues for Prefilled Glass Syringes

Compatibility issues have been reported between certain prefilled needleless glass syringes and pin-activated needleless intravenous (IV) access systems, the US Food and Drug Administration (FDA) announced yesterday.

Connection attempts may cause the pin to break, thus clogging the syringe or causing damage to the IV tubing and/or needleless connector that requires reestablishment of IV access.

The resulting delay in drug administration could cause serious harm to patients requiring urgent treatment, according to an alert sent from MedWatch, the FDA's safety information and adverse event reporting program.

Most of the reports have reflected issues with prefilled syringes containing adenosine, made by Teva (NDC 00703-8781-23), Sagent (NDC 25021-0301-72), Baxter (NDC 10019-0063-08 [07]), and Wockhardt (NDC 64679-0630-01 [02]); problems with amiodarone-filled syringes from Sagent/Gland have also been reported (NDC 25021-0302-73).

Healthcare professionals are advised to check for affected products and to consider stocking adenosine vials or prefilled plastic syringes as a back-up measure in crash carts, operating room pharmacies, and emergency drug boxes/caches.

"While FDA is concerned about this incompatibility, we are most concerned with situations in which a delay in delivery of the drug could potentially result in serious harm to patients," the agency noted in a news release.

As a result, the FDA has initiated a review of all currently marketed prefilled needleless glass syringes intended for use with needleless IV access systems for which delays in drug administration could cause life-threatening harm. The FDA is also working with manufacturers to correct the problem and identify additional mitigation strategies while reviewing the problem to determine the appropriate regulatory actions.

More information on the announcement is available on the FDA Web site.

Adverse events related to use of needleless prefilled glass syringes should be reported to the FDA's MedWatch reporting program by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at http://www.fda.gov/medwatch, or by mail to 5600 Fishers Lane, Rockville, Maryland 20852-9787.

~ Above Photo From ---> http://www.medxl.com/home.html

Views: 1281

Tags: access, dangers, glass, intravenous, needleless, of, pin-activated, prefilled, syringe, syringes, More…systems


You need to be a member of QD Syringe Systems® to add comments!

Join QD Syringe Systems®

© 2024   Created by Christopher Green.   Powered by

Badges  |  Report an Issue  |  Terms of Service